Beyfortus’ second campaign is “a service to children” and will “streamline” the organization of care, says the campaign coordinator

The second campaign of immunization of infants against RSV, the respiratory syncytial virus, the main cause of bronchiolitis, which begins Saturday, September 14, “will be a service to children”said on France Inter Christèle Gras-Le Guen, professor of pediatrics at the Nantes University Hospital, coordinator of the Beyfortus treatment campaign in France.

This new campaign is good news for “children’s health” and for “their families”says Christèle Gras-Le Guen. She points out “the weight of illness”that of the “work stoppages for parents”as well as the “painfulness of this disease”. So it is the children and families who are “the big beneficiaries” of this new wave of treatment, judges the pediatrician.

The campaign coordinator also believes that “the organization of care” will also be improved. “We hope to make the patient journey smoother and avoid the huge traffic jams that we experience every winter and which are detrimental above all to children and their families.” “If it can make the teams’ operations smoother, that will be appreciated in all cases.”rejoices Christèle Gras-Le Guen.

In 2023, parents massively adopted Beyfortus, a preventive treatment against bronchiolitis, marketed in France by Sanofi. But there was a shortage of doses. France had received barely 200,000 for just under 700,000 births in the country. This year, France will receive nearly 600,000 doses, three times more than in 2023.